Tonghua Golden Horse: Wholly-owned subsidiary plans to acquire controlling stake in Bajia Pharmaceutical.

Tonghua Golden Horse announced that on August 6, 2026, the companys wholly-owned subsidiary, Guilin Golden Horse, signed a Merger Intent Agreement with Bajia Pharmaceuticals, intending to acquire its controlling stake. Bajia Pharmaceuticals holds 23 research and development patents for drugs and has three Class 1 new drug clinical approvals. The due diligence period is 60 days, and the exclusivity period is 90 days. The transaction price is to be negotiated and will require subsequent decision-making and approval procedures. The target company has unresolved enforcement cases, and there is uncertainty regarding the market launch of its products under development, presenting various uncertainties for this merger.